Aclaris Therapeutics (ACRS) Retained Earnings (2014 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly Retained Earnings of $22000.0 in Q1 2026, up 100.0% quarter-over-quarter from -$967.8 million in Q4 2025, and up 100.0% on a YoY basis from $10999.9 in Q1 2025.
Aclaris Therapeutics (ACRS) Retained Earnings (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Retained Earnings history runs 13 years deep, the most recent figure standing at $22000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 100.0% year-over-year to $22000.0; the TTM figure through Mar 2026 stood at $22000.0 (up 100.0% YoY), while the FY2025 annual figure was -$967.8 million, down 997815.46% from the prior year.
- Retained Earnings was $22000.0 for Q1 2026 at Aclaris Therapeutics, up from -$967.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $482000.0 in Q2 2025 to a low of -$967.8 million in Q4 2025.
- Historically, Retained Earnings has averaged -$384.6 million across 5 years, with a median of -$1.5 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 191.51% in 2024, then tumbled 997815.46% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$897000.0 in 2022, then surged by 88.18% to -$106000.0 in 2023, then soared by 191.51% to $97000.0 in 2024, then sank by 997815.46% to -$967.8 million in 2025, then jumped by 100.0% to $22000.0 in 2026.
- The last three Retained Earnings figures came in at $22000.0 (Q1 2026), -$967.8 million (Q4 2025), and -$948.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | 22,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22,000.00 |
| Dec 31, 2025 | -967.78 Mn |
| Sep 30, 2025 | -948.00 Mn |
| Jun 30, 2025 | 482,000.00 |
| Mar 31, 2025 | -917.95 Mn |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Jun 30, 2024 | -798.70 Mn |
| Mar 31, 2024 | -787.70 Mn |
| Dec 31, 2023 | -106,000.00 |
| Sep 30, 2023 | -769.31 Mn |
| Jun 30, 2023 | -1.11 Mn |
| Mar 31, 2023 | -710.48 Mn |
| Dec 31, 2022 | -897,000.00 |
| Sep 30, 2022 | -1.47 Mn |
| Jun 30, 2022 | -634.73 Mn |
| Mar 31, 2022 | -972,000.00 |
| Dec 31, 2021 | -224,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -551.50 Mn |